NVCT

In the past six months, Nuvectis Pharma significantly expanded its pipeline by in-licensing ex-China rights to NXP100 and NXP200 from Haisco Pharmaceutical Group in June 2026, diversifying into complement-mediated diseases and enhancing its oncology pipeline. In July 2026, Ciprocopan (NXP100) received its first global marketing approval in China for PNH. The company completed a successful public offering in July 2026, raising $115 million to extend its cash runway into the first half of fiscal year 2029. However, the NXP800 program experienced a clinical trial failure due to safety and efficacy concerns. Several analysts initiated or updated coverage, with Cantor Fitzgerald initiating an "Overweight" rating in August 2026, UBS Group and Roth Capital setting $33.00 price targets in July 2026 (Roth upgrading to a "buy"), and Loop Capital setting a $40.00 target price in September 2026, resulting in a consensus "Moderate Buy" rating with an average price target of $36.25. The stock has experienced significant volatility, including a surge of approximately 145% since April 30, 2026, and a 97% gain over three months due to pipeline optimism, alongside pullbacks. Nuvectis Pharma reported net losses of $7.0 million for Q2 2026 and $6.1 million for Q1 2026, with no product revenue. Insider buying activity was observed, with key individuals like Charles Mosseri Marlio acquiring shares in June 2026. Shareholders have also experienced dilution, with total shares outstanding growing by 28% in the past year.